Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Key Points: The FDA-approved drug atovaquone is a novel, clinically available inhibitor of STAT3 at standard human plasma concentrations. Atovaquone shows anticancer efficacy in vitro, in vivo, and in a retrospective study of AML patient outcomes after atovaquone treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Reynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M., Jeanne, M., Sala-Torra, O., Radich, J. P., & Passegué, E. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.012 · Cited by 335
Birth, D., Kao, W.-C., & Hunte, C. (2014) · Nature Communications · doi:10.1038/ncomms5029 · Cited by 205
Cited by
Oxidative Phosphorylation as an Emerging Target in Cancer Therapy
Ashton, T. M., McKenna, W. G., Kunz-Schughart, L. A., & Higgins, G. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3070 · Cited by 1,135
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Salas, A., Hernandez-Rocha, C., Duijvestein, M., Faubion, W., McGovern, D., Vermeire, S., Vetrano, S., & Vande Casteele, N. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0273-0 · Cited by 635
Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map
Huynh, J., Chand, A., Gough, D., & Ernst, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0090-8 · Cited by 504
Dong, J., Cheng, X.-D., Zhang, W.-D., & Qin, J.-J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00629 · Cited by 232
Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing
Chan, J., Wang, X., Turner, J. A., Baldwin, N. E., & Gu, J. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz006 · Cited by 50
“…et al., 2016b; Liu et al., 2015a), neurodegenerative diseases (Sandor et al., 2017; Siavelis et al., 2016), gastrointestinal and liver diseases (Hicks et al., 2017), stroke and sepsis (Chen et al., 2015b) and cancers (Hsieh et al., 2016; Liu et al., 2015b; Xiang et al., 2016; Zhao et al., 2016).”
Background
Metadata
- Authors
- Xiang, M., Kim, H., Ho, V. T., Walker, S. R., Bar-Natan, M., Anahtar, M., Liu, S., Toniolo, P. A., Kroll, Y., Jones, N., Giaccone, Z. T., Heppler, L. N., Ye, D. Q., Marineau, J. J., Shaw, D., Bradner, J. E., Blonquist, T., Neuberg, D., Hetz, C., Stone, R. M., Soiffer, R. J., & Frank, D. A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-10-06
- Volume
- 128
- Issue
- 14
- Pages
- 1845-1853
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2509469063
- Cited by
- 109
- References
- 5
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. https://app.cochat.ai/papers/10.1182/blood-2015-07-660506
- The paper
- Xiang, M., Kim, H., Ho, V. T., Walker, S. R., Bar-Natan, M., Anahtar, M., Liu, S., Toniolo, P. A., Kroll, Y., Jones, N., Giaccone, Z. T., Heppler, L. N., Ye, D. Q., Marineau, J. J., Shaw, D., Bradner, J. E., Blonquist, T., Neuberg, D., Hetz, C., . . . Frank, D. A. (2016). Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood. https://doi.org/10.1182/blood-2015-07-660506
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.